Free Trial
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Price, News & Analysis

Kezar Life Sciences logo
$4.58 +0.05 (+1.10%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$4.66 +0.08 (+1.83%)
As of 07/9/2025 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kezar Life Sciences Stock (NASDAQ:KZR)

Key Stats

Today's Range
$4.45
$4.70
50-Day Range
$3.83
$4.79
52-Week Range
$3.62
$9.18
Volume
24,966 shs
Average Volume
52,011 shs
Market Capitalization
$33.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50
Consensus Rating
Hold

Company Overview

Kezar Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

KZR MarketRank™: 

Kezar Life Sciences scored higher than 83% of companies evaluated by MarketBeat, and ranked 197th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kezar Life Sciences has received no research coverage in the past 90 days.

  • Read more about Kezar Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Kezar Life Sciences are expected to decrease in the coming year, from ($4.39) to ($8.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kezar Life Sciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kezar Life Sciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kezar Life Sciences has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Kezar Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    0.85% of the float of Kezar Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kezar Life Sciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kezar Life Sciences has recently increased by 7.52%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Kezar Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Kezar Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.85% of the float of Kezar Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kezar Life Sciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kezar Life Sciences has recently increased by 7.52%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Kezar Life Sciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Kezar Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,531.00 in company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Kezar Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kezar Life Sciences' insider trading history.
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo
Kezar Life Sciences reports topline results from PORTOLA trial
See More Headlines

KZR Stock Analysis - Frequently Asked Questions

Kezar Life Sciences' stock was trading at $6.72 at the start of the year. Since then, KZR shares have decreased by 31.8% and is now trading at $4.58.

Kezar Life Sciences, Inc. (NASDAQ:KZR) issued its earnings results on Tuesday, May, 13th. The company reported ($2.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.56) by $0.29.

Shares of Kezar Life Sciences reverse split on the morning of Wednesday, October 30th 2024.The 1-10 reverse split was announced on Monday, October 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Kezar Life Sciences (KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kezar Life Sciences investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT) and Zomedica (ZOM).

Company Calendar

Last Earnings
5/13/2025
Today
7/09/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KZR
CIK
1645666
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$70.00
Low Price Target
$9.00
Potential Upside/Downside
+762.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$83.74 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7 million
Price / Cash Flow
N/A
Book Value
$16.02 per share
Price / Book
0.29

Miscellaneous

Free Float
6,546,000
Market Cap
$33.48 million
Optionable
Not Optionable
Beta
0.60
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:KZR) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners